Skip to main content
SNN logo

Smith & Nephew plc (SNN) Stock: Price, Forecast & Analyst Target

Smith & Nephew plc (SNN) — MoonshotScore 84/100 (Exceptional band), calculated Nov 18, 2026. Price $29.83 (0.00%), as of the Nov 20, 2026 trading session; market cap $12.5B. Expected results Mar 1, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 16.58× (cash as of Jun 27, 2026) · expected results Mar 1, 2027

$29.83 $0.00 (0.00%) Market Cap $12.5B

Smith & Nephew plc · SNN · NYSE · Healthcare · Medical - Devices

Research dated 2026-09-13: Smith & Nephew supplies healthcare providers with joint implants, trauma systems, arthroscopy equipment, ear, nose and throat solutions, and advanced wound products; it is a procedural medical-device platform, not merely a maker of replacement joints. Product launches must now offset competitive pressure in the United States while higher profit becomes dependable cash generation.

Price as of Nov 20, 2026

Key Statistics

84 of 100

MoonshotScore v2 · Smith & Nephew (SNN)

Exceptional
Business Quality Elite (87)
Financial Safety Okay (54)
Valuation Fair (70)
Growth Durability Compounding (90)
Momentum Rising (75)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and elite growth, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Compounding; Momentum: Rising.

  • quarterly revenue $3.10B (Q2 FY2026, quarter ended Jun 27, 2026)
  • Altman Z 3.10 · Piotroski F 8
  • ROE 11.9% · ROA 5.2% · current ratio 2.14

Helping: business quality, an attractive price, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for SNN (53 recorded, newest six shown)
RecordedScoreBand
85Exceptional
85Exceptional
85Exceptional
84Exceptional
84Exceptional
84Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$29.83
Change on the day0.00%
52-week range$26.12–$37.09
Market capitalisation$12.5B—
Price / earnings (trailing)20.00
Shares traded on the day1.23M
Beta (volatility vs the S&P 500)0.69
Dividends per share (last 12 months)$0.79
Dividend yield (last 12 months)2.60%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $26, high $37, latest $30. 2 reported quarters marked, 2 above and 0 below the recorded estimate. 1 other dated event marked. $37 $26 high $37 Mar 2, 2026 · Earnings results · reported above the recorded estimate · close $371Aug 4, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $302Aug 4, 2026 · Earnings results · reported above the recorded estimate · close $303 Oct 17, 2025 Nov 20, 2026 · $30 $36Oct 17, 2025$37Oct 31, 2025$33Nov 14, 2025$33Nov 28, 2025$33Dec 12, 2025$33Dec 26, 2025$34Jan 9, 2026$33Jan 23, 2026$35Feb 6, 2026$36Feb 20, 2026$34Mar 6, 2026$32Mar 20, 2026$32Apr 2, 2026$34Apr 17, 2026$31May 1, 2026$30May 15, 2026$30May 29, 2026$31Jun 12, 2026$30Jun 26, 2026$31Jul 10, 2026$31Jul 24, 2026$30Aug 7, 2026$29Aug 21, 2026$29Sep 4, 2026$28Sep 18, 2026$26Oct 2, 2026$29Oct 16, 2026$30Oct 30, 2026$31Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • Now taking into account revenue performance, we now expect underlying revenue growth of around 4% for 2026.

    Deepak Nath · Statement from

  • We are seeing the impact of competitor launches in the U.S., but we expect growth to strengthen in the second half as we launch EVOS, Pelvic and ramp up TRIGEN MAX.

    John Rogers · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for Smith & Nephew (SNN): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Moderate
Growth Durability Strong
Momentum Moderate

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Debt/Equity Weak
ROE Neutral
Gross Margin Strong

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Smith & Nephew (SNN), and what does it report?

Short answer

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally.

Demand comes from procedures and wound treatment: healthcare providers buy implants and fracture-stabilization systems, instruments and visualization equipment for minimally invasive surgery, and products used across acute, chronic and postoperative wounds.

Reported sales place orthopaedics, sports medicine, and ear, nose and throat products in a combined category, with Advanced Wound Management reported separately. Most revenue comes from the combined category, so consolidated growth primarily reflects surgical devices even though wound care remains a meaningful business.

2 · Latest results

What do the latest results show for Smith & Nephew (SNN)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $3.10B.

Annual revenue and net income have advanced across recent reporting periods, and the latest comparable-period figures continued that pattern. Revenue rose, gross profit and operating profit increased, and net income edged higher, although revenue was below the immediately preceding period. Reported earnings have also cleared estimates lately after earlier misses.

Management attributes current pressure in the United States to competitor launches and expects EVOS, Pelvic, and TRIGEN MAX to strengthen growth as their rollouts progress. That is a management expectation rather than an explanation already established by the reported results.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$3.10B Jun 27, 2026
Latest quarter · R&D
$150.00M Jun 27, 2026
Latest quarter · SG&A
$1.60B Jun 27, 2026
Latest quarter · FMP standardized operating result
$448.00M Jun 27, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Jun 27, 2026$3.10B$150.00M$1.60B$448.00M
Dec 31, 2025$3.20B$203.00M$1.52B$365.00M
Jun 30, 2025$2.96B$143.00M$1.52B$429.00M
Dec 31, 2024$2.98B$206.00M$1.40B$329.00M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$3.10B Aug 4, 2026
Latest report · revenue estimate
$3.46B Aug 4, 2026
Latest report · revenue vs estimate
Below estimate Aug 4, 2026
Latest report · EPS vs estimate
Above estimate Aug 4, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Aug 4, 2026$3.10B$3.46B$0.9460$0.9390
Mar 2, 2026$3.20B$2.77B$1.1800$1.1600
Aug 5, 2025$2.96B$1.53B$0.8580$0.7900
Feb 25, 2025$2.98B$2.96B$0.9380$0.9200
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$3.10B$303M$0.70 (diluted)
Q4 FY2025$3.20B$332M$0.76 (diluted)
Q2 FY2025$2.96B$293M$0.68 (diluted)
Q4 FY2024$2.98B$198M$0.46 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Smith & Nephew (SNN)?

Short answer

Cash and short-term investments were $754.00M at the Jun 27, 2026 balance-sheet date. Operating cash flow was $450.00M for the quarter ended Jun 27, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Operating cash flow has stayed positive throughout the displayed series, and recent generation remained above capital spending. Cash and short-term investments have also recovered to the highest point in that series, while liquidity ratios and quality screens indicate a sound near-term financial footing.

Debt still substantially exceeds cash and investments, leaving Smith & Nephew dependent on continued cash conversion rather than balance-sheet cash alone. Competitive pressure that slows surgical-device growth, or weaker working-capital performance while restructuring costs rise, would reduce the cash available for debt service and distributions.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$450.00M Jun 27, 2026
Previous quarter · operating cash flow
$889.00M Dec 31, 2025
Period endOperating cash flowCapital expenditure (reported)
Jun 27, 2026$450.00M−$190.00M
Dec 31, 2025$889.00M−$294.00M
Jun 30, 2025$396.00M−$139.00M
Dec 31, 2024$749.00M−$209.00M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Smith & Nephew (SNN)?

Short answer · as of

The next earnings report is expected on Mar 1, 2027.

The scheduled earnings update needs to pair continued revenue expansion with evidence that EVOS, Pelvic, and TRIGEN MAX are gaining traction against competitor launches in the United States. Consensus estimates assume further sales and earnings growth, raising the importance of execution in the combined surgical-device portfolio.

Cash conversion deserves equal attention. Management expects profit growth and working-capital discipline to support free cash flow despite a temporary increase in restructuring costs; operating cash flow, capital spending, and the cash balance will show whether that bridge is holding. Recent broker downgrades add context to the execution test without determining its outcome.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. We continue to expect free cash flow in 2026 of around $800 million, driven by profit growth and continued focus on working capital, offset by a modest temporary increase in restructuring costs.

    John Rogers ·

2 more statements are quoted under Upcoming events

What the records here don't tell us

  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Smith & Nephew compare with its peers?

Short answer

Smith & Nephew's score ranks 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Compared with a device maker concentrated on joint reconstruction, Smith & Nephew reaches further across the procedure: implants and trauma hardware sit alongside arthroscopy tools, visualization systems, tissue-resection equipment, and ear, nose and throat products. Advanced Wound Management adds exposure to wound dressings, bioactive products, negative-pressure therapy, and hydrosurgery.

That breadth can spread demand across surgical and wound-care settings, but the reporting structure combines several surgical franchises into a large category. Investors therefore see less divisional detail than the product range itself might suggest.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Neurocrine Biosciences, Inc. (NBIX) Named competitor$156.59 Nov 19, 2026$15.9B95 5-pillar Nov 18, 2026
Globus Medical, Inc. (GMED) Same industry, near in market value$68.60 Nov 19, 2026$9.09B94 5-pillar Nov 18, 2026
Medpace Holdings, Inc. (MEDP) Named competitor$610.54 Nov 20, 2026$17.1B92 5-pillar Nov 18, 2026
Penumbra, Inc. (PEN) Same industry, near in market value$319.12 Nov 20, 2026$12.6B92 5-pillar Nov 18, 2026
Centene Corporation (CNC) Named competitor$63.78 Nov 20, 2026$31.6B91 5-pillar Nov 18, 2026
STERIS plc (STE) Same industry, near in market value$254.76 Nov 19, 2026$24.7B87 5-pillar Nov 18, 2026
Insulet Corporation (PODD) Same industry, near in market value$133.17 Nov 20, 2026$9.24B85 5-pillar Nov 18, 2026
Smith & Nephew (SNN) — this page$29.83$12.5B84
Align Technology, Inc. (ALGN) Same industry, near in market value$155.17 Nov 20, 2026$10.9B83 5-pillar Nov 18, 2026
Zimmer Biomet Holdings, Inc. (ZBH) Same industry, near in market value$101.10 Nov 20, 2026$19.1B79 5-pillar Nov 18, 2026
Koninklijke Philips N.V. (PHG) Same industry, near in market value$28.61 Nov 20, 2026$28.0B78 5-pillar Nov 18, 2026
Bio-Rad Laboratories, Inc. (BIO) Same industry, near in market value$358.90 Nov 20, 2026$9.65B77 5-pillar Nov 18, 2026
Royalty Pharma plc (RPRX) Named competitor$67.72 Nov 19, 2026$38.9B73 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$33.88 – $33.88
Consensus target
$33.88
Median target
$33.88

Consensus record · Captured .

Measured against a quoted price of $29.83 (as of Nov 20, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
8.1% Period end Sep 30, 2026
Previous quarter · ownership
8.5% Prior to period end Sep 30, 2026
Reporting holders
260 Period end Sep 30, 2026
Previous quarter · holders
298 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Goldman Sachs Group INC4,204,122
River Road Asset Management, LLC2,927,860
Brandes Investment Partners, LP2,413,144
Lmr Partners Llp2,246,567
Morgan Stanley1,916,394

Tracked investors

Which of the 16 named investors we follow held SNN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SNN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Smith & Nephew (SNN)?

Read these with our analysis →

What Investors Ask About Smith & Nephew (SNN) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

What does Smith & Nephew sell beyond hip and knee implants?

The portfolio includes trauma and extremities systems, arthroscopy instruments and visualization equipment, tissue-resection devices, ear, nose and throat solutions, wound dressings, bioactive products, negative-pressure therapy, and hydrosurgery systems.

Why do EVOS, Pelvic, and TRIGEN MAX matter to Smith & Nephew?

Management has tied these launches and product ramps to an expected improvement in United States growth after competitor launches pressured performance. Their commercial progress is therefore a direct test of the stated recovery mechanism.

How important is Advanced Wound Management to Smith & Nephew?

Advanced Wound Management is a substantial but smaller revenue stream than the combined orthopaedics, sports medicine, and ear, nose and throat category. It broadens the company beyond implants through wound care, bioactives, regenerative products, and treatment devices.

Can Smith & Nephew operating cash flow support its dividend and debt load?

Recent operating cash flow has covered capital spending, and distributions have continued, but debt remains well above cash and investments. Ongoing support therefore depends on sustained cash conversion, including the working-capital improvement management expects.

What is the SNN stock price today?

The last price recorded for Smith & Nephew plc (SNN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the SNN price target?

The analyst consensus price target for Smith & Nephew plc (SNN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 84 figures on this page — 2 from SEC filings and earnings calls, 73 from Financial Modeling Prep (FMP), 3 with no recorded source, 5 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Legal name; Business description; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • 1. What is Smith & Nephew (SNN), and what does it report?: Business description; Revenue by segment; Sector / industry (provider taxonomy)
  • 2. What do the latest results show for Smith & Nephew (SNN)?: Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Smith & Nephew (SNN)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Management outlook — dated call excerpts
  • 4. What should you watch next at Smith & Nephew (SNN)?: Next earnings report; Analyst revenue and earnings estimates (average); Management outlook — dated call excerpts; Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Analyst actions, most recent per firm
  • 5. How does Smith & Nephew compare with its peers?: Business description; Revenue by segment
  • FAQ: What does Smith & Nephew sell beyond hip and knee implants?: Business description
  • FAQ: Why do EVOS, Pelvic, and TRIGEN MAX matter to Smith & Nephew?: Management outlook — dated call excerpts
  • FAQ: How important is Advanced Wound Management to Smith & Nephew?: Revenue by segment; Business description
  • FAQ: Can Smith & Nephew operating cash flow support its dividend and debt load?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash against market value; Recent dividends paid; Next scheduled dividend; Management outlook — dated call excerpts
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.